Author:
O'Donohoe Alan,Gill Michael
Abstract
AbstractThis article reviews the current knowledge regarding the hepatic cytochrome P450 system, with particular reference to its effect on psychotherapeutic medication. The metabolic processes – by which drugs are broken down in the liver by cytochrome P450 enzymes – are affected by genetic variation between individuals, inhibition and induction of these enzymes by other drugs, disease and age. Genetic influences and enzyme inhibition/induction are discussed in particular detail in this article.
Publisher
Cambridge University Press (CUP)
Subject
History and Philosophy of Science,Psychiatry and Mental health,Applied Psychology
Reference51 articles.
1. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6-the source of the sparteine/debrisoquine oxidation polymorphism [letter]
2. The P450 Superfamily: Updated Listing of All Genes and Recommended Nomenclature for the Chromosomal Loci
3. Biotransformation of caffeine, perxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon inducible cytochrome P450 in human liver microsomes;Campbell;Drug Metab Dispos Biol Fate Chem,1987
4. Coadministration of Fluvoxamine Increases Serum
5. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylase-clinical implications;Bertilsson;Lancet,1981